Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man

Journal of Pharmaceutical Sciences

Volumn 92, Issue 5, 2003, Pages 985-994

  Levy, Gerhard ^a   Mager, Donald E ^a   Cheung, Wing K ^a,b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Human; Mathematical modeling; Nonlinear phamacokinetics; Physiological based pharmacokinetic modeling; Rats; Target mediated drug disposition; Warfarin

Indexed keywords

WARFARIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MATHEMATICAL MODEL; NONHUMAN; PHARMACOKINETICS; RAT;

EID: 0037407352     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10345     Document Type: Article

References (29)

1. Levy G. 1994. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
2. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
3. Cheung WK, Levy G. 1989. Comparative pharmacokinetics of coumarin anticoagulants XLIX: Nonlinear tissue distribution of S-warfarin in rats. J Pharm Sci 78:541-546.
4. Hazelett SE, Preusch PC. 1988. Tissue distribution and warfarin sensitivity of vitamin K epoxide reductase. Biochem Pharmacol 37:929-934.
5. 1 2,3 epoxide reductase system from rat liver. J Pharm Pharmacol 53:481-486.
6. Thijssen HH, Baars LG. 1989. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase. Biochem Pharmacol 38:1115-1120.
7. Cheung WK. 1984. Dissertation. Pharmacokinetics of warfarin in rats: Role of serum protein binding and tissue distribution. Buffalo: University at Buffalo, State University of New York.
8. King SY, Joslin MA, Raudibaugh K, Pieniaszek HJ Jr. Benedek IH. 1995. Dose-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm Res 12:1874-1877.
9. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide. Los Angeles: Biomedical Simulations Resource.
10. Mandel MJ, Sapirstein LA. 1962. Effect of angiotensin infusion on regional blood flow and regional vascular resistance in the rat. Circ Res 10:807-816.
11. Altman PL, Dittmer DS. 1974. Biology data book, 2nd ed., Vol. 3. Bethesda: Federation of American Societies for Experimental Biology.
12. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. 1971. Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133.
13. Jansky J, Hart JS. 1968. Cardiac output and organ blood flow in warm- and cold-acclimated rats exposed to cold. Can J Physiol Pharmacol 46:653-659.
14. Schemmel R, Mickelsen O, Gill JL. 1970. Dietary obesity in rats: Body weight and body fat accretion in seven strains of rats. J Nutr 100:1041-1048.
15. Mosterd JJ, Thijssen HH. 1992. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat. J Pharmacol Exp Ther 260:1081-1085.
16. Takada K, Levy G. 1979. Comparative pharmacokinetics of coumarin anticoagulants. XLIII. Concentration-dependent hepatic uptake of warfarin in rats. J Pharm Sci 68:1569-1571.
17. Takada K, Levy G. 1980. Comparative pharmacokinetics of coumarin anticoagulants. XLIV. Dosedependent pharmacokinetics of warfarin in rats. J Pharm Sci 69:9-14.
18. Yacobi A, Levy G. 1975. Comparative pharmacokinetics of coumarin anticoagulants. XIV. Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. J Pharm Sci 64:1660-1664.
19. Levy G. 1986. Effect of protein binding on the pharmacologic activity of drugs as exemplified by warfarin. In: Reidenberg MM, Erill S, editors. Drug-protein binding. New York: Praeger Publishers, pp 317-331.
20. Thijssen HH, Baars LG. 1987. Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. J Pharmacol Exp Ther 243:1082-1088.
21. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
22. Thijssen HH, Janssen YP. 1994. Target-based warfarin pharmacokinetics in the rat: The link with the anticoagulant effect. J Pharmacol Exp Ther 270: 554-558.
23. Wallin R, Martin LF. 1985. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 76:1879-1884.
24. Covell DG, Abbrecht PH, Berman M. 1983. The effect of hepatic uptake on the disappearance of warfarin from the plasma of rats: A kinetic analysis. J Pharmacokinet Biopharm 11:127-145.
25. Yacobi A, Levy G. 1975. Effect of plasma protein binding on the anticoagulant action of warfarin in rats. Res Commun Chem Pathol Pharmacol 12: 405-408.
26. Cain D, Hutson SM, Wallin R. 1998. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb Haemost 80:128-133.
27. Palareti G, Legnani C. 1996. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300-313.
28. Yamanaka Y, Yamano M, Yasunaga K, Shike T, Uchida K. 1990. Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats. Thromb Res 57:205-214.
29. White JC, Goldman ID. 1976. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro. Mol Pharmacol 12:711-719.